Top Markets
#1 Akedo Akedo +73.71%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.71%
#4 Cross Cross +43.52%
#5 Black Phoenix Black Phoenix +33.78%
#6 Cap Cap +25.61%
#7 Velvet Velvet +25.32%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.62%
#9 DoubleZero DoubleZero +12.53%
#10 Palladium Network Palladium Network +12.46%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Lipidor AB (publ) Lipidor AB (publ)

Lipidor AB (publ)

LIPI
Rank in Stocks #39101
Lipidor AB (publ), a Swedish pharmaceutical company founded in Danderyd in... Lipidor AB (publ), a Swedish pharmaceutical company founded in Danderyd in 2009, specializes in developing medicinal products. Its core business centers on creating treatments for various skin conditions, including psoriasis, bacterial skin infections, and atopic dermatitis. The company's product pipeline includes AKP-01, which is currently in Phase III clinical trials for psoriasis, while other formulations like AKP-02 (also for psoriasis) and AKP-03 and AKP-07 (for eczema) are in earlier, preclinical development stages. Beyond its own drug candidates, Lipidor manufactures and supplies active pharmaceutical ingredients (APIs). These APIs are incorporated into products addressing a broad spectrum of therapeutic applications, such as managing psoriasis, microbial infections, inflammation, fungal issues, local pain relief, acne, wound healing, eczema, and migraines. Lipidor also caters to the animal health market, offering a line of spray-on skin care products for dogs, cats, and horses. Additionally, it develops consumer health items designed for purposes like antibacterial action, antiseptic care, moisturizing, disinfection, and treating acne and warts. In a key strategic alliance, Lipidor has partnered with Cannassure Therapeutics Ltd. This collaboration aims to advance topical medicinal cannabis products specifically formulated to alleviate skin inflammations and psoriatic lesions.
Share Price
$0.02243487
Last synced: 2025-06-04
Market Cap
$650.09K
Change (1 day)
0.39%
Change (1 year)
0.00%
Country
SE
Trade Lipidor AB (publ) (LIPI)

Category

Healthcare
P/E ratio for Lipidor AB (publ) (LIPI)
P/E ratio as of August 2026 TTM: -6.74
According to Lipidor AB (publ) latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.74. At the end of 2023 the company had a P/E ratio of -1.27.
P/E ratio history for Lipidor AB (publ) from 2016 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -6.74 1.05%
2024 -6.67 424.78%
2023 -1.27 146.20%
2022 -0.52 -95.36%
2021 -11.14 -45.54%
2020 -20.46 -15.06%
2019 -24.09 51.11%
2018 -15.94 -60.17%
2017 -40.02 60.31%
2016 -24.97 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 40.73 -704.28%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 29.64 -539.71%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 123.01 -1,925.10%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 22.25 -430.10%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 36.58 -642.73%
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.